CD47 and cancer: Furthermore, recent studies have revealed that the combination of anti-PD1/PD-L1 and inhibition of CD47/SIRPα signaling developed more effective cancer immunotherapy through activating macrophages phagocytosis and antitumor effects which can further activate CD8+ T cells (189, 190).